Filing Flows › iSpecimen (ISPC) › Q1 2025
iSpecimen (ISPC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 19, 2025
iSpecimen (ISPC) reported revenue of $1.1M for the first quarter 2025 (Q1 2025), -54% from a year earlier and -28% from the quarter before. Operating margin was -154.9%, net loss $1.7M (156.8% of revenue).
iSpecimen, Q1 2025: revenue $1.1M (-54% year over year), operating margin -154.9%, net loss $1.7M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -28% | -54% |
| Operating profit | −$1.6M | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $1.1M in Q1 2025, down 54% year over year and down 28% from the previous quarter. Product was the largest line at 92% of revenue. Product lost $1.2M year over year (down 54%), 94% of the total change.
Operating costs exceeded revenue by $1.6M, an operating margin of -154.9%. Total costs fell 49% while revenue fell 54%. The quarter ended with a net loss of $1.7M, narrower than the previous quarter's $6.0M loss.
Operating cash flow was −$1.1M. Non-cash charges added back $433K of depreciation and amortization and $16K of share-based compensation. Working capital and other items added $114K.
Questions
What was iSpecimen's revenue in the first quarter 2025?
iSpecimen (ISPC) reported revenue of $1.1M for the first quarter 2025 (Q1 2025), -54% from a year earlier and -28% from the quarter before.
Was iSpecimen profitable in the first quarter 2025?
Operating loss was $1.6M (-154.9% of revenue) and net loss $1.7M.
Source: iSpecimen 10-Q on SEC EDGAR.